A kind of capecitabine quick-release pellets and preparation method thereof

A capecitabine, immediate-release technology, applied in the field of medicine, can solve the problems of increased drug concentration, multiple components, uneven mixing, etc., and achieve the effects of reducing irritation, high dissolution rate, and reducing adverse reactions
CN103156877BActive Publication Date: 2015-11-25SHENZHEN NEPTUNUS PHARMA RES INST CO LTD
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHENZHEN NEPTUNUS PHARMA RES INST CO LTD
Publication Date
2015-11-25

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to a capecitabine immediate-release pellet and a preparation method thereof. The capecitabine immediate-release pellet includes the compositions of capecitabine, an excipient, a disintegrating agent and an adhesive. The particle size of the pellet is 0.1-10 mm. The extrusion granulator technology is used in the present invention to prepare the capecitabine immediate-release pellets and the pellets are directly filled into capsules, thus the production process is greatly simplified. The method is simple and reliable. The capecitabine immediate-release pellets prepared by the present invention are good in reproducibility and high in yield.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a capecitabine quick-release pellet and a preparation method thereof. Background technique

[0002] Capecitabine (capecitabine) is an oral fluoropyrimidine nucleoside prodrug with targeting effect obtained by chemically modifying the chemical structure of fluorouracil (FU). Its chemical name is: 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine (pyrimidine nucleoside), and its structural formula is:

[0003]

[0004] Capecitabine was developed by Roche with the product name "xeloda". It was approved for marketing in the United States in April 1998, and was subsequently listed in Switzerland and other countries. After oral administration, it passes through the gastrointestinal wall intact, and is catalyzed by liver carboxylesterase to 5'-deoxy-5-fluorocytidine (5'-DFCR), and then catalyzed by cytidine deaminase in liver and tumor cells It is converted into 5'-de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More